Swedish digital asset manager Virtune has launched what it claims is Europe's most cost-efficient Sui exchange-traded product (ETP) on Euronext Paris, marking another step in the company's expansion across European markets. The Virtune Sui ETP, with the ticker VRTU, provides investors with exposure to the Sui cryptocurrency through a regulated, physically backed investment vehicle. This launch comes as Virtune continues to build its position as one of the leading issuers of regulated crypto ETPs in Europe.

The new ETP features an industry-leading 0.95% annual management fee, making it the most cost-efficient Sui ETP available to European investors. Virtune plans to further expand the product's distribution by listing it on local German exchanges, including gettex and Tradegate, to improve accessibility for German investors. The company has established itself as a trusted provider in the digital asset space, serving over 150,000 investors since its launch just over two years ago.

Security and regulatory compliance remain central to Virtune's approach, with Coinbase serving as the crypto custodian for all of the company's ETPs. The underlying crypto assets are held in cold storage, providing institutional-grade security for investors. This infrastructure supports Virtune's commitment to offering European investors secure, transparent, and regulated access to digital asset markets through traditional investment channels.

Christopher Kock, CEO of Virtune, emphasized the company's mission to make innovative digital assets more accessible to investors. "We are excited to launch the most cost-efficient Sui ETP in Europe, reinforcing our mission to make innovative digital assets more accessible to investors," Kock stated. The launch strengthens Virtune's position as it manages more than $475 million in assets across its product offerings, continuing its growth trajectory in the European digital asset management landscape.

Nobel Prize officials in Sweden have issued a stark warning that Donald Trump's administration's cuts to scientific funding could jeopardize the United States' position as the world's leading research nation. According to officials from the Royal Swedish Academy of Sciences, the president's actions since taking office in January—including cutting billions in research funding, attacking academic freedoms, and overseeing mass layoffs of scientists across federal agencies—pose a significant threat to America's scientific dominance with potential global repercussions.

The United States currently leads all nations in Nobel science laureates, a position largely attributed to decades of sustained investment in basic science and strong academic freedoms. Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel prizes in physics, chemistry, and economics, noted that "In the post-war period, the US has taken over Germany's role as the world's leading scientific nation. When they now start cutting research funding, it threatens the country's position." This assessment comes as Nobel Prize announcements approach next week in Stockholm and Oslo, where US-based researchers traditionally feature prominently among recipients.

Specific data from independent database Grant Watch reveals the scale of the funding reductions. Since January, the National Institutes of Health have terminated 2,100 research grants totaling approximately $9.5 billion, along with $2.6 billion in contracts. The affected research spans critical areas including gender studies, health effects of global warming, Alzheimer's disease, and cancer research. While efforts to restore some funding are reportedly underway, significant uncertainty persists about the long-term impact on these scientific initiatives.

The concerns extend beyond immediate funding cuts to broader implications for scientific progress. Thomas Perlmann, secretary general of the committee that awards the Nobel Prize for Medicine, emphasized that it was "no coincidence that the US has by far the most Nobel laureates," linking America's scientific success directly to its historical support for research. Additional fields facing potential impact include vaccine development, climate change research, and diversity, equity, and inclusion initiatives, raising questions about whether the current policy direction could trigger a broader scientific brain drain from American institutions.